-
If you purchased shares of Celladon Corp (NASDAQ:CLDN) and currently hold any of those NASDAQ:CLDN shares, you have certain options and you should contact the Shareholders Foundation, Inc.
-
To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Investigation Overview
December 03, 2015 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Celladon Corp (NASDAQ:CLDN), was announced concerning whether the takeover of Celladon Corp. is unfair to NASDAQ:CLDN stockholders.
The investigation by a law firm concerns whether certain officers and directors of Celladon Corp breached their fiduciary duties owed to NASDAQ:CLDN investors in connection with the proposed acquisition.
On November 18, 2015 Celladon Corp (NASDAQ:CLDN) and Eiger BioPharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that they have entered into a merger agreement under which the stockholders of Eiger would become the majority owners of Celladon, and the operations of Celladon and Eiger would be combined.
However, given that shares of Celladon Corp (NASDAQ:CLDN) traded in March 2015 at $26.69 per share, the investigation concerns whether the offer is unfair to NASDAQ:CLDN stockholders. More specifically, the investigation concerns whether the Celladon Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
